Is Cochlear Limited (CHEOY) a Buy, Sell, or Hold?
OTC : CHEOY
Cochlear Limited — News
$39.06 USD
$0.22 (0.57%)
- Volume
- 11.03K
- Average Volume
- 86.74K
- Market Capitalization
- $5.11B
- P/E Ratio
- 21.14
- Dividend Yield
- 3.85%
- Price Target
- $117.00
- Year High
- $105.60
- Year Low
- $31.82
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.81
- Current Ratio
- $2.46
| Source | Headline |
|---|---|
|
Envoy Medical Reports Positive 12-Month Data Showing Continued Improvement in Speech Perception in Study of First-of-Its-Kind Fully Implanted Cochlear Implant
Mean CNC word recognition scores for Stage 1 cohort improved to 53.2% at 12 months from 15.2% pre-implantation, a 38.0 percentage point gain that continued to build on the 24.0 percentage point improvement reported at 6 months White Bear Lake, Minnesota--(Newsfile Corp. - July 14, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced positive 12-month data from the first 10 participants in Stage 1 of its pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant. The Stage 1 cohort demonstrated a mean Consonant-Nucleus-Consonant ("CNC") word recognition score of 53.2% at their 12-month visits, up from a mean pre-implantation baseline of 15.2% — a 38.0 percentage point improvement. newsfilecorp.com - 2026-07-14 09:17:00 |
|
Better Hearing and Whole-Body Health: What to Know About MRI Access with Cochlear Implants
During Better Hearing and Speech Month, understanding MRI compatibility is an important part of long-term hearing care LONE TREE, Colo., May 29, 2026 /PRNewswire/ -- May is Better Hearing and Speech Month, a month dedicated to raising awareness about the importance of hearing health. prnewswire.com - 2026-05-29 14:13:00 |
|
Envoy Medical Reports Landmark Accomplishments, Advancing Toward FDA Approval of First-of-Its-Kind Fully Implanted Cochlear Implant
Company Completes Historic Trial Enrollment, Secures Transformational Financing, and Sees Promising Early Clinical Data Presented at Industry Conferences White Bear Lake, Minnesota--(Newsfile Corp. - May 11, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today reported first quarter 2026 results and landmark achievements that advance the Company another step closer toward commercialization of its investigational Acclaim® cochlear implant. "The first quarter of 2026 marked a transformative period for Envoy Medical, highlighted by the completion of enrollment in our pivotal clinical trial and the successful execution of a significant financing," said Brent Lucas, Chief Executive Officer of Envoy Medical. newsfilecorp.com - 2026-05-11 08:00:00 |
|
MED-EL USA Presents Real World Clinical Insights to Support Tailored Hearing Solutions at the 2026 American Cochlear Implant Association Meeting
DURHAM, N.C.--(BUSINESS WIRE)-- #ACIA2026--Hearing implant leader MED-EL USA is announcing two upcoming symposia at CI2026, the annual meeting of the American Cochlear Implant Association (ACIA) in Chicago. The meeting also celebrates the recent U.S. Food and Drug Administration (FDA) approval of an expanded indication for MED-EL cochlear implants for children seven months and older with bilateral sensorineural hearing loss (SNHL). MED-EL's cochlear implant system is the only FDA-approved option for infant. businesswire.com - 2026-04-29 10:30:00 |
